BPMC - Blueprint Medicines Corp - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

BPMC is currently covered by 19 analysts with an average price target of $149.62. This is a potential upside of $20.16 (15.57%) from yesterday's end of day stock price of $129.46.

Blueprint Medicines Corp's activity chart (see below) currently has 279 price targets and 267 ratings on display. The stock rating distribution of BPMC is 86.11% BUY, 9.72% HOLD and 4.17% SELL.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 85.43% with an average time for these price targets to be met of 273.21 days.

Highest price target for BPMC is $150, Lowest price target is $100, average price target is $124.24.

Most recent stock forecast was given by DEREK ARCHILA from WELLS FARGO on 17-Jun-2025. First documented stock forecast 26-May-2015.

Currently out of the existing stock ratings of BPMC, 62 are a BUY (86.11%), 7 are a HOLD (9.72%), 3 are a SELL (4.17%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$129

$-0.46 (-0.36%)

$151

1 months 19 days ago
(17-Jun-2025)

10/11 (90.91%)

$0.77 (0.60%)

110

Sell

$129

$-0.46 (-0.36%)

$76

2 months 1 days ago
(04-Jun-2025)

11/13 (84.62%)

$0.9 (0.70%)

229

Buy

$125

2 months 2 days ago
(03-Jun-2025)

16/18 (88.89%)

$35.25 (39.28%)

292

Buy

$129

$-0.46 (-0.36%)

$129

2 months 3 days ago
(02-Jun-2025)

3/3 (100%)

$1.21 (0.95%)

132

Buy

$130

$0.54 (0.42%)

$130

2 months 3 days ago
(02-Jun-2025)

13/24 (54.17%)

$2.21 (1.73%)

73

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is BPMC (Blueprint Medicines Corp) average time for price targets to be met?

On average it took 273.21 days on average for the stock forecasts to be realized with a an average price target met ratio 85.43

Which analyst has the current highest performing score on BPMC (Blueprint Medicines Corp) with a proven track record?

RENI BENJAMIN

Which analyst has the most public recommendations on BPMC (Blueprint Medicines Corp)?

Reni Benjamin works at JMP and has 2 price targets and 6 ratings on BPMC

Which analyst is the currently most bullish on BPMC (Blueprint Medicines Corp)?

Salveen Richter with highest potential upside - $38.54

Which analyst is the currently most reserved on BPMC (Blueprint Medicines Corp)?

Liana Moussatos with lowest potential downside - -$54.46

Blueprint Medicines Corp in the News

KIT Inhibitors Market Growth: Key Trends and Future Projections in the 7MM Upto 2034 | DelveInsight

The KIT inhibitors market remains highly competitive, driven by established players such as ONO Pharmaceutical and Blueprint Medicines, among others. At the same time, companies like Celldex Therapeutics, Cogent Biosciences, and Blueprint Medicines¸, among others, are actively advancing pipeline candidates across various stages of development. This sustained R&D activity reflects ongoing innovation and intensifying competition...

Blueprint Medicines Stock Up Despite Lower-Than-Expected Q1 Earnings

Blueprint Medicines Corporation BPMC reported first-quarter 2025 adjusted loss of 74 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 42 cents. The adjusted figure excludes the one-time equity investment gain of $50 million recorded in the reported quarter, following the closing of GSK’s acquisition of IDRx. The company incurred a...
Show more

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?